BLITZ Heart Failure

Study Overview
=================
Brief Summary
-----------------
To evaluate if Italian Cardiologists are treating Heart Failure (HF) patients according to International guidelines and if a structured educational program can improved their adherence.

Detailed Description
-----------------
Multicentre, cross-sectional, prospective, non-interventional, observational study designed to evaluate the level of adherence to current ESC guidelines recommendations in both acute and chronic HF patients enrolled in each participating center and to verify if a specific HF educational intervention composed by an educational web based program of data collection and face to face meetings is able to improve adherence to guidelines recommendations evaluated during a second enrollment period.

Official Title
-----------------
BLITZ Heart Failure

Conditions
-----------------
Heart Failure

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All consecutive patients with chronic HF and those admitted for acute (de novo) or worsening chronic HF. Chronic HF: any NYHA class (I-IV). Acute HF Only patients in NYHA class III or IV, or with pulmonary edema or cardiogenic shock for whom an IV therapy specific for HF (diuretic, vasodilators, vasopressors) is administered. Any gender. Any etiology of HF. Any level of EF. Written informed consent. Exclusion Criteria: - Age <18 years. Inclusion in registries or trials that can influence, by protocol, the clinical management of patients. Patients already enrolled in the BLITZ HF (by another participating centre or in the first enrollment period).

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Adherence to current guideline | To assess number of patients managed and treated following the 2016 ESC Heart Failure Gudelines (acute HF, chronic HFrEF, chronic HFmrEF, chronic HFpEF). | Enrollment | 
| Patients managed and treated following International Guideline | Patients treatment in phase 1 versus phase 3 | 24 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Mortality | Death from all-causes, for cardiovascular causes, for HF | 12 months Follow-up | 
| Morbidity | Hospital admissions from all-causes, for cardiovascular causes, for HF | 12 months Follow-up | 
| Indication to heart failure device implantation | The rate of patients with chronic HFrEF with an indication to ICD and/or CRT planned in clinical practice | Enrollement | 
| Prescription rate of disease modifying drugs | The rate of patients with HFrEF receiving all the drugs recommended by current guidelines: ACE-Is/ARBs, betablockers and MRAs, in the absence of specific contraindications/intolerance. | Enrollment | 
| Oral anticoagulation prescription in patients with AF | Rate of patients treated with oral anticoagulants in case of AF | Enrollment | 
| Use of ARNI | The rate of implementation of a new drug approach (ARNI) for patients with HF and EF ≤35% | Enrollment | 
| Creatinine and EF evaluation | The rate of CHF patients with an available measure of EF and of creatinine. | Enrollment | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Acute Heart Failure, Chronic Heart Failure, Guideline adherence, Clinical registry